NAS:PRCT Key Ratios
| Market Cap $ M | 1,205.61 |
| Enterprise Value $ M | 1,055.20 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 3.54 |
| Price/Sales | 3.50 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 337.00 |
| EPS (TTM) $ | -1.94 |
| Beneish M-Score | -2.47 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 2.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -9.95 |
| EV-to-EBITDA | -10.27 |
| PEG | -- |
| Shares Outstanding M | 57.27 |
| Net Margin (%) | -32.54 |
| Operating Margin % | -33.86 |
| Pre-tax Margin (%) | -32.46 |
| Quick Ratio | 5.35 |
| Current Ratio | 6.55 |
| ROA % (ttm) | -21.96 |
| ROE % (ttm) | -30.16 |
| ROIC % (ttm) | -53.62 |
| Dividend Yield % | -- |
| Altman Z-Score | 3.96 |
PRCT Number of Guru Trades
PRCT Volume of Guru Trades
Gurus Latest Trades with NAS:PRCT
NAS:PRCT is held by these investors
PROCEPT BioRobotics Corp Insider Transactions
Guru Commentaries on NAS:PRCT
Procept Biorobotics, the US listed surgical robotics group, has continued to drift through much of the year on very limited negative newsflow, reflecting the general focus away from the sector overall. While Procept did suffer from a temporary industry-wide shortage of saline solution earlier in the year, this proved to be a blip and cannot explain the continued gentle decline for the share price. Our 3-5 year investment horizon is designed to look through these events and we have continued to add to the holding on weakness, backed by solid progress in sales and profits.
PROCEPT BioRobotics was mentioned as one of the smaller market cap and higher multiple positions that faced pressure during the quarter. The letter notes that while they had encouraging operating results, they were offset by broader market conditions affecting life sciences positions. The manager highlights that the healthcare sector is experiencing volatility due to uncertainties introduced by the new administration and personnel turnover at the FDA, which raises questions about drug development and approvals.
News about NAS:PRCT
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
